3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Inflammatory Breast Neoplasms
1
Glioblastoma
1
COVID-19
1
Adenocarcinoma of Lung
1
Interventions
BNT162 Vaccine
2
2019-nCoV Vaccine mRNA-1273
2
tocilizumab
1
sotrovimab
1
proxalutamide
1
bemcentinib
1
Therapeutics
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Sodium Chloride
1
Radiotherapy
1
Patient Reported Outcome Measures
1
Janus Kinase Inhibitors
1
Influenza Vaccines
1
Hydroxychloroquine
1
HuMax-IL8
1
Gelsolin
1
Diagnostic Tests, Routine
1
Decision Support Techniques
1
COVID-19 Vaccines
1
Blood Specimen Collection
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
COVID-19
×
bemcentinib
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts